Beam Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $2.52B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $114.11M | $2.33 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $8.47M | $-1.00 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $30.07M | $-1.09 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
Press releases
Announcements Beam Therapeutics filed with the SEC
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The Power of Predictability JANUARY 2026 NASDAQ: BEAM
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Beam Therapeutics Reports Third Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Announces Pricing of Underwritten Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Results of operations · EX-99.1 to Form 8-K
PRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 Financial Results & ASH Abstracts Investor Webcast November 5, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
PRECISION GENETIC MEDICINES THROUGH BASE EDITING JANUARY 2024 NASDAQ: BEAM
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
Results of operations · EX-99 to Form 8-K
BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
Other events · EX-99.1 to Form 8-K
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K